Summary: The latest GINA recommendations, following the 2019 recommendations, emphasize the important role of inhaled corticosteroids (ICS) in asthma therapy at all treatment steps. These drugs are the foundation of therapy oriented toward the inflammatory process and airway remodeling. In the treatment of mild asthma, the on-demand combination of ICS + LABA or a daily low dose of ICS (in step 2) is advised. An important drug in this area is ciclesonide - a drug with a number of beneficial properties for the patient. This drug is a pro-drug that converts to the active molecule only after bronchial administration. It is characterized by high pulmonary deposition, low oral deposition and a generally favorable safety profile. Due to its small molecule, it is characterized as an extra fine particle steroid. Clinical and observational studies show significant benefits of ciclesonide in the treatment of mild asthma in lung function parameters and asthma control compared to other fine particle steroids.